September 2023
1. ROWAN C
   In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk.
   Ann Intern Med. 2023 Sep 5. doi: 10.7326/J23-0069.
   

   >> Share

   
   July 2023
2. AL-JABRI R, Afif W
   In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events.
   Ann Intern Med. 2023;176:JC82.
   

   >> Share

   
   October 2022
3. OLIVER D, Talley NJ
   In active Crohn disease, risankizumab increased clinical remission and endoscopic response at 12 wk.
   Ann Intern Med. 2022 Oct 4. doi: 10.7326/J22-0080.
   

   >> Share

   
   
4. FORBES GM
   In active UC, upadacitinib induced and maintained remission.
   Ann Intern Med. 2022;175:JC113.
   

   >> Share

   
   September 2022
5. MEYER A, Neumann A, Drouin J, Weill A, et al
   Benefits and Risks Associated With Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease : A Nationwide Emulation Trial.
   Ann Intern Med. 2022 Sep 27. doi: 10.7326/M22-0819.
   

   >> Share

   
   December 2021
6. 
   Correction: Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.
   Ann Intern Med. 2021;174:1780.
   

   >> Share

   
   October 2021
7. MELMED GY, Botwin GJ, Sobhani K, Li D, et al
   Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.
   Ann Intern Med. 2021 Oct 12. doi: 10.7326/M21-2483.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share